Alejandra Camacho-Soto1, Anat Gross1, Susan Searles Nielsen1, Neelendu Dey2, Brad A Racette3. 1. Department of Neurology, Washington University School of Medicine, St. Louis, MO, United States. 2. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, WA, United States. 3. Department of Neurology, Washington University School of Medicine, St. Louis, MO, United States; School of Public Health, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa. Electronic address: racetteb@wustl.edu.
Abstract
INTRODUCTION: Gastrointestinal (GI) dysfunction precedes the motor symptoms of Parkinson's disease (PD) by several years. PD patients have abnormal aggregation of intestinal α-synuclein, the accumulation of which may be promoted by inflammation. The relationship between intestinal α-synuclein aggregates and central nervous system neuropathology is unknown. Recently, we observed a possible inverse association between inflammatory bowel disease (IBD) and PD as part of a predictive model of PD. Therefore, the objective of this study was to examine the relationship between PD risk and IBD and IBD-associated conditions and treatment. METHODS: Using a case-control design, we identified 89,790 newly diagnosed PD cases and 118,095 population-based controls >65 years of age using comprehensive Medicare data from 2004-2009 including detailed claims data. We classified IBD using International Classification of Diseases version 9 (ICD-9) diagnosis codes. We used logistic regression to calculate odds ratios (ORs) and 95% confidence intervals (CIs) to evaluate the association between PD and IBD. Covariates included age, sex, race/ethnicity, smoking, Elixhauser comorbidities, and health care use. RESULTS: PD was inversely associated with IBD overall (OR = 0.85, 95% CI 0.80-0.91) and with both Crohn's disease (OR = 0.83, 95% CI 0.74-0.93) and ulcerative colitis (OR = 0.88, 95% CI 0.82-0.96). Among beneficiaries with ≥2 ICD-9 codes for IBD, there was an inverse dose-response association between number of IBD ICD-9 codes, as a potential proxy for IBD severity, and PD (p-for-trend = 0.006). CONCLUSION: IBD is associated with a lower risk of developing PD.
INTRODUCTION:Gastrointestinal (GI) dysfunction precedes the motor symptoms of Parkinson's disease (PD) by several years. PDpatients have abnormal aggregation of intestinal α-synuclein, the accumulation of which may be promoted by inflammation. The relationship between intestinal α-synuclein aggregates and central nervous system neuropathology is unknown. Recently, we observed a possible inverse association between inflammatory bowel disease (IBD) and PD as part of a predictive model of PD. Therefore, the objective of this study was to examine the relationship between PD risk and IBD and IBD-associated conditions and treatment. METHODS: Using a case-control design, we identified 89,790 newly diagnosed PD cases and 118,095 population-based controls >65 years of age using comprehensive Medicare data from 2004-2009 including detailed claims data. We classified IBD using International Classification of Diseases version 9 (ICD-9) diagnosis codes. We used logistic regression to calculate odds ratios (ORs) and 95% confidence intervals (CIs) to evaluate the association between PD and IBD. Covariates included age, sex, race/ethnicity, smoking, Elixhauser comorbidities, and health care use. RESULTS:PD was inversely associated with IBD overall (OR = 0.85, 95% CI 0.80-0.91) and with both Crohn's disease (OR = 0.83, 95% CI 0.74-0.93) and ulcerative colitis (OR = 0.88, 95% CI 0.82-0.96). Among beneficiaries with ≥2 ICD-9 codes for IBD, there was an inverse dose-response association between number of IBD ICD-9 codes, as a potential proxy for IBD severity, and PD (p-for-trend = 0.006). CONCLUSION:IBD is associated with a lower risk of developing PD.
Authors: Ruth F Villarán; Ana M Espinosa-Oliva; Manuel Sarmiento; Rocío M De Pablos; Sandro Argüelles; María J Delgado-Cortés; Verónica Sobrino; Nico Van Rooijen; José L Venero; Antonio J Herrera; Josefina Cano; Alberto Machado Journal: J Neurochem Date: 2010-08-19 Impact factor: 5.372
Authors: Aree Witoelar; Iris E Jansen; Yunpeng Wang; Rahul S Desikan; J Raphael Gibbs; Cornelis Blauwendraat; Wesley K Thompson; Dena G Hernandez; Srdjan Djurovic; Andrew J Schork; Francesco Bettella; David Ellinghaus; Andre Franke; Benedicte A Lie; Linda K McEvoy; Tom H Karlsen; Suzanne Lesage; Huw R Morris; Alexis Brice; Nicholas W Wood; Peter Heutink; John Hardy; Andrew B Singleton; Anders M Dale; Thomas Gasser; Ole A Andreassen; Manu Sharma Journal: JAMA Neurol Date: 2017-07-01 Impact factor: 18.302
Authors: Laura Dwyer-Lindgren; Ali H Mokdad; Tanja Srebotnjak; Abraham D Flaxman; Gillian M Hansen; Christopher Jl Murray Journal: Popul Health Metr Date: 2014-03-24
Authors: Alexander Grotemeyer; Rhonda Leah McFleder; Jingjing Wu; Jörg Wischhusen; Chi Wang Ip Journal: Front Immunol Date: 2022-05-18 Impact factor: 8.786
Authors: Jade E Kenna; Megan C Bakeberg; Anastazja M Gorecki; Alfred Chin Yen Tay; Samantha Winter; Frank L Mastaglia; Ryan S Anderton Journal: Mov Disord Clin Pract Date: 2021-01-05